Author
Listed:
- Jerry H. Houl
(University of Texas MD Anderson Cancer Center)
- Zu Ye
(University of Texas MD Anderson Cancer Center)
- Chris A. Brosey
(University of Texas MD Anderson Cancer Center)
- Lakshitha P. F. Balapiti-Modarage
(The University of Arkansas at Little Rock
The University of Arkansas for Medical Sciences)
- Sarita Namjoshi
(University of Texas MD Anderson Cancer Center)
- Albino Bacolla
(University of Texas MD Anderson Cancer Center)
- Daniel Laverty
(Harvard University, School of Public Health)
- Brian L. Walker
(The University of Arkansas at Little Rock
The University of Arkansas for Medical Sciences)
- Yasin Pourfarjam
(University of Cincinnati)
- Leslie S. Warden
(University of Texas MD Anderson Cancer Center)
- Naga Babu Chinnam
(University of Texas MD Anderson Cancer Center
UTHealth Graduate School of Biomedical Sciences)
- Davide Moiani
(University of Texas MD Anderson Cancer Center)
- Roderick A. Stegeman
(Washington University School of Medicine)
- Mei-Kuang Chen
(University of Texas MD Anderson Cancer Center
UTHealth Graduate School of Biomedical Sciences)
- Mien-Chie Hung
(University of Texas MD Anderson Cancer Center
China Medical University)
- Zachary D. Nagel
(Harvard University, School of Public Health)
- Tom Ellenberger
(Washington University School of Medicine)
- In-Kwon Kim
(University of Cincinnati
Washington University School of Medicine)
- Darin E. Jones
(The University of Arkansas at Little Rock
The University of Arkansas for Medical Sciences)
- Zamal Ahmed
(University of Texas MD Anderson Cancer Center)
- John A. Tainer
(University of Texas MD Anderson Cancer Center)
Abstract
Poly(ADP-ribose)ylation (PARylation) by PAR polymerase 1 (PARP1) and PARylation removal by poly(ADP-ribose) glycohydrolase (PARG) critically regulate DNA damage responses; yet, conflicting reports obscure PARG biology and its impact on cancer cell resistance to PARP1 inhibitors. Here, we found that PARG expression is upregulated in many cancers. We employed chemical library screening to identify and optimize methylxanthine derivatives as selective bioavailable PARG inhibitors. Multiple crystal structures reveal how substituent positions on the methylxanthine core dictate binding modes and inducible-complementarity with a PARG-specific tyrosine clasp and arginine switch, supporting inhibitor specificity and a competitive inhibition mechanism. Cell-based assays show selective PARG inhibition and PARP1 hyperPARylation. Moreover, our PARG inhibitor sensitizes cells to radiation-induced DNA damage, suppresses replication fork progression and impedes cancer cell survival. In PARP inhibitor-resistant A172 glioblastoma cells, our PARG inhibitor shows comparable killing to Nedaplatin, providing further proof-of-concept that selectively inhibiting PARG can impair cancer cell survival.
Suggested Citation
Jerry H. Houl & Zu Ye & Chris A. Brosey & Lakshitha P. F. Balapiti-Modarage & Sarita Namjoshi & Albino Bacolla & Daniel Laverty & Brian L. Walker & Yasin Pourfarjam & Leslie S. Warden & Naga Babu Chin, 2019.
"Selective small molecule PARG inhibitor causes replication fork stalling and cancer cell death,"
Nature Communications, Nature, vol. 10(1), pages 1-15, December.
Handle:
RePEc:nat:natcom:v:10:y:2019:i:1:d:10.1038_s41467-019-13508-4
DOI: 10.1038/s41467-019-13508-4
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:10:y:2019:i:1:d:10.1038_s41467-019-13508-4. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.